Patents by Inventor Ladislaus Maria Broersen
Ladislaus Maria Broersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11457657Abstract: The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (i) DHA and optionally EPA, and (ii) medium-chain triglycerides, preferably at least 2 wt % C8 and C10 medium-chain triglycerides based on weight of the fatty acids; and wherein the composition has a ketogenic weight ratio between 1.4:1 and 3:1, for use in the treatment of traumatic brain injury (TBI).Type: GrantFiled: January 10, 2020Date of Patent: October 4, 2022Assignee: N.V. NutriciaInventors: Robert Johan Joseph Hageman, Ladislaus Maria Broersen, Nick Van Wijk
-
Patent number: 11141397Abstract: The invention pertains to a composition for use in (a) treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; (b) improving the efficacy of levodopa (L-DOPA) in treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; and/or (c) reducing L-DOPA associated side effects, preferably involuntary movements selected from the group consisting of choreiform, dystonic and dyskinetic movements, in the treatment of impaired motor skills in a mammal suffering from Parkinson's Disease, comprising co-administering to the subject L-DOPA and a composition comprising therapeutically effective amounts of: (i) at least one of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA); (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.Type: GrantFiled: December 6, 2019Date of Patent: October 12, 2021Assignee: N.V. NutriciaInventors: Ladislaus Maria Broersen, Nick Van Wijk, Amos Attali
-
Patent number: 10821120Abstract: The invention pertains to the use of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more preferably DHA and EPA, for the manufacture of a composition or medicament for treating, reducing and/or preventing neuroinflammation and/or symptoms associated with neuroinflammation in a subject in need thereof, as well as for reducing microglia activation, and/or for treating, reducing and/or preventing symptoms associated with excessive activation of microglia; and/or for reducing the secretion of inflammatory cytokines, preferably IL-6, and/or for treating, reducing and/or preventing symptoms associated with excessive secretion of inflammatory cytokines, in a subject in need thereof.Type: GrantFiled: June 9, 2017Date of Patent: November 3, 2020Assignee: N.V. NutriciaInventors: Sofia Lopes Da Silva, Ladislaus Maria Broersen, Robert Johan Joseph Hageman, Jan Maarten Verkuijl
-
Publication number: 20200146326Abstract: The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (i) DHA and optionally EPA, and (ii) medium-chain triglycerides, preferably at least 2 wt % C8 and C10 medium-chain triglycerides based on weight of the fatty acids; and wherein the composition has a ketogenic weight ratio between 1.4:1 and 3:1, for use in the treatment of traumatic brain injury (TBI).Type: ApplicationFiled: January 10, 2020Publication date: May 14, 2020Inventors: Robert Johan Joseph Hageman, Ladislaus Maria Broersen, Nick Van Wijk
-
Publication number: 20200108036Abstract: The invention pertains to a composition for use in (a) treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; (b) improving the efficacy of levodopa (L-DOPA) in treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; and/or (c) reducing L-DOPA associated side effects, preferably involuntary movements selected from the group consisting of choreiform, dystonic and dyskinetic movements, in the treatment of impaired motor skills in a mammal suffering from Parkinson's Disease, comprising co-administering to the subject L-DOPA and a composition comprising therapeutically effective amounts of: (i) at least one of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA); (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.Type: ApplicationFiled: December 6, 2019Publication date: April 9, 2020Applicant: N.V. NUTRICIAInventors: Ladislaus Maria BROERSEN, Nick VAN WIJK, Amos ATTALI
-
Publication number: 20190175622Abstract: The invention pertains to the use of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more preferably DHA and EPA, for the manufacture of a composition or medicament for treating, reducing and/or preventing neuroinflammation and/or symptoms associated with neuroinflammation in a subject in need thereof, as well as for reducing microglia activation, and/or for treating, reducing and/or preventing symptoms associated with excessive activation of microglia; and/or for reducing the secretion of inflammatory cytokines, preferably IL-6, and/or for treating, reducing and/or preventing symptoms associated with excessive secretion of inflammatory cytokines, in a subject in need thereof.Type: ApplicationFiled: June 9, 2017Publication date: June 13, 2019Applicant: N.V. NUTRICIAInventors: Sofia LOPES DA SILVA, Ladislaus Maria BROERSEN, Robert Johan Joseph HAGEMAN, Jan Maarten VERKUIJL
-
Publication number: 20130230503Abstract: The present invention relates to the use of a preparation, especially a nutritional preparation, for the prevention or treatment of anxiety in a subject, especially in a depressed subject, and depression. More specifically, the present invention relates to the use of a preparation, especially a nutritional preparation, for the prevention or treatment of anxiety or depression in a subject that is non-responsive to SSRI medication. Furthermore, the invention relates to the use of a preparation, especially anutritional preparation, for regulating neurogenesis. The preparation comprises the following components: a) at least one ?-3 polyunsaturated fatty acid (PUFA); b) at least two phospholipids, selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine or any mixture thereof; and c) one or more compounds which are a factor in the serotonin metabolism, selected from the group of B vitamins and tryptophan.Type: ApplicationFiled: September 3, 2010Publication date: September 5, 2013Inventors: Judith Homberg, Amanda Johanne Kiliaan, Ladislaus Maria Broersen
-
Patent number: 8445458Abstract: A composition comprising (a) one or more ?-3 fatty acids selected from DHA, DPA and EPA, (b) uridine or its equivalent, and (c) a methyl donor, useful in the treatment of a person having characteristics of a prodromal dementia patient. The characteristics include e.g. a level of more than 350 ng Total-tau per liter cerebrospinal fluid (CSF), and a weight ratio of abeta-42/Phospho-tau-181 of less than 6.5 in CSF.Type: GrantFiled: June 20, 2008Date of Patent: May 21, 2013Assignee: N. V. NutriciaInventors: Robert Johan Joseph Hageman, Patrick Joseph Gerardus Hendrikus Kamphuis, Ladislaus Maria Broersen
-
Publication number: 20100323982Abstract: A composition comprising (a) one or more ?-3 fatty acids selected from DHA, DPA and EPA, (b) uridine or its equivalent, and (c) a methyl donor, useful in the treatment of a person having characteristics of a prodromal dementia patient. The characteristics include e.g. a level of more than 350 ng Total-tau per litre cerebrospinal fluid (CSF), and a weight ratio of abeta-42/Phospho-tau-181 of less than 6.5 in CSF.Type: ApplicationFiled: June 20, 2008Publication date: December 23, 2010Inventors: Robert Johan Joseph Hageman, Patrick Joseph Gerardus Hendrikus Kamphuis, Ladislaus Maria Broersen
-
Publication number: 20040247699Abstract: There is provided a method for the prevention or treatment of overweight. More particularly, the invention relates to a method for the treatment or prevention of overweight in a mammal wherein the method comprises the enteral administration of Bacopa plant material to said mammal in an amount effective to reduce the mammal's overweight or to prevent the occurrence of overweight.Type: ApplicationFiled: December 20, 2002Publication date: December 9, 2004Inventors: Bernardina Johanna Martina Delsing, Gerrit Jan Wiite, Rene John Raggers, Ladislaus Maria Broersen